Table 5

Levels of thrombophilic and coagulation factors or presence of thrombotic risk factors in 90 patients with chronic hepatitis B or C in relation to their histological staging

FactorStaging 0–3 (n=65)Staging 4–6 (n=25)p Value
Quantitative values are expressed as mean (SD).
aCL, anticardiolipin; APC, activated protein C.
*All six patients were heterozygous for the prothrombin 20210A mutation.
†Significant thrombotic risk factors included protein C deficiency, antithrombin III deficiency, plasminogen deficiency, and APC resistance.
IgG aCL antibodies (U/m) 5.1 (1.8) 5.6 (1.9) 0.21
IgM aCL antibodies (U/m) 6.1 (4.1) 6.3 (3.7) 0.84
aCL antibodies elevated (n (%)) 4 (6.2) 2 (8.0)1.00
    (IgG/IgM/IgG+IgM) (0/3/1) (1/1/0)
Protein C levels (%)104 (23) 84 (25)<0.001
Protein C deficiency (n (%)) 2 (3.1) 6 (24.0) 0.007
Protein S levels (%) 84 (25) 71 (22) 0.02
Protein S deficiency (n (%)) 16 (24.6) 11 (44.0) 0.12
Antithrombin III levels (%)108 (14) 93 (19)<0.001
Antithrombin III deficiency (n (%)) 3 (4.8) 7 (28.0) 0.005
Plasminogen (mg/dl) 97 (14) 90 (14) 0.045
Plasminogen deficiency (n (%)) 1 (1.5) 4 (19.0) 0.03
APC ratio 2.8 (0.4) 2.8 (0.4) 0.74
APC resistance (n (%)) 0 2 (8.0) 0.075
Prothrombin 20210A mutation* (n (%)) 5 (7.7) 1 (4.0) 0.88
Factor VIII levels (%)157 (61)192 (70) 0.02
Factor VIII levels elevated (n (%)) 34 (52.3) 17 (68.0)0.27
Factor IX levels (%)121 (41)121 (36) 0.95
Factor XI levels (%)104 (38) 99 (38) 0.57
Factor XII levels (%)106 (41)111 (24) 0.61
≥1 coagulation factor deficiency (n (%)) 12 (18.5) 2 (8.0) 0.33
≥1 significant thrombotic risk factor† (n (%)) 6 (9.2) 11 (44.0)<0.001
≥1 any thrombotic risk factor (n (%)) 42 (64.6) 19 (76.0) 0.43
≥2 any thrombotic risk factors (n (%)) 19 (29.2) 14 (56.0) 0.03